January 22, 2021
Business News

New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma


SANTA MONICA, Calif.–()–Kite, a Gilead Company (Nasdaq: GILD), today announced follow-up results from the pivotal ZUMA-2 trial of Tecartus™ (brexucabtagene autoleucel, formerly KTE-X19) in adult patients with relapsed or refractory mantle cell lymphoma (MCL). At a median follow-up of 17.5 months (n=60 evaluable for efficacy), 92 percent of patients had achieved a response, including 67 percent with a complete response (CR). Secondary endpoints of median duration of response, progression-free survival (PFS) and overall survival (OS) all were not yet reached. These data were presented at the 62nd ASH Annual Meeting and Exposition (Abstract #1120).

“Patients with mantle cell lymphoma face a disease that often…



Click here to view the original article.

Related Posts

You might also like ...

Crescent NV Enters Into a Financing Agreement With LDA Capital Limited
Rory Channer Joins BehaVR as Chief Commercial Officer
HanesBrands Names Joe Cavaliere Group President, Global Innerwear